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Introduction
The field of mechanical circulatory support is evolving rapidly and new data are
published at a rate that can be overwhelming. The last two years, we published
reviews entitled “What Did We Learn about VADs in 2014?”(1) and “What Did We
Learn about VADs in 2015?”(2). Both papers were well received – the full texts
were downloaded 570 and 440 times, respectively, by readers around the globe.
Encouraged by this, we wrote the present review, where, like before, we
summarized some of the publications from 2016 that we think are particularly
important. There may be slight overlap with the end of 2015, because some
papers are being published online first.
Readers who wish to supplement this review or to argue with the author’s
statements or article selection are encouraged to do so on our Facebook page at
https://www.facebook.com/TheVADJournal. Comments are welcome via the link
“Readers comments” on our homepage http://uknowledge.uky.edu/vad/.
Finally, many sources were so recently published, electronically ahead of print,
that full bibliography is not available yet. In the References, we put doi for each
source without volume/issue/pages.
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HeartMate III
As last year, the greatest focus of interest for the mechanical circulatory support
(MCS) community was Heartmate III (HMIII) (St. Jude Medical, Pleasanton,
California) which already received the Conformité Européene (CE) Mark approval
in Europe for advanced heart failure patients (HF), both as bridge to
transplantation and as destination therapy. For the benefit of the readers, we will
reiterate the key features of the device (3):


Intrapericardial position



Fully magnetically levitated rotor



Rotor speed range of 3,000 to 9,000 revolutions per minute (rpms)



Maximum flow rate of 10 L/min



No friction, heat generation, wear and tear



Wide gaps for the blood flow (blood flow paths) through the device
(10-20 times wider than in currently used pumps)



Pump speed change 30 times per minute to create pulsatility



External portion of the driveline can be changed without pump
exchange



Texturing of the internal surface with titanium microspheres

These features are designed to achieve following effects:


Minimization of blood stasis



Minimization of shear stress to blood



Development of a pseudo-intima on the inside of the pump to
prevent pump thrombosis



Maximizing of the aortic valve opening

This pump has some distinct features on echo (Figure 1) (4):


Reverberation artifacts during color flow Doppler examination
(Figure 2)



Device-induced pulsatility of blood flows (Figure 3).
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Figure 1. Transesophageal echo: inflow cannula. From Magunia et al.(4), with
permission.

Figure 2. Transesophageal echo: the turbulent pattern is due to a reverberation
artifact and occurs when inflow and rotor are directly opposite of the ultrasound
beam source. From Magunia et al.(4), with permission.
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Figure 3. Transesophageal echo: pulsatility of blood flow. The pulsed wave
Doppler shows the heart’s cycle and pump-augmented baseline inflow into the
device. Within 15 ms, pump speeds are decreased by 2,000 rpm from baseline,
then increased by 4,000 rpm before being adjusted back to previously
programmed values. From Magunia et al.(4), with permission.
From hemodynamic standpoint, this pump performs well. A ramp test with
simultaneous hemodynamic and echocardiographic recordings in 16 patients with
HMIII measured the changes with the speed ranging 4,600 rpms to 6,200 rpms.
Remarkably, a majority of patients (10 of 16, 62.5%) had normal parameters of left
ventricular (LV) (pulmonary capillary wedge pressure) and right ventricular (RV)
function (central venous pressure) already at the mean original speed of 5,306 +/148 rpms. With gradual speed increase, per each step of 100 rpms, cardiac output
increased by 0.08 +/- 0.08 L/min (total change 1.25 +/- 1.20 L/min) and pulmonary
capillary wedge pressure decreased by 0.48 +/- 0.27 mm Hg (total change -6.13
+/- 3.72 mm Hg). There were no significant changes in central venous pressure or
systolic blood pressure. LV end-diastolic dimension decreased at a rate of -0.15
+/- 0.09 cm per 100 rpms. The speed was adjusted based on test results to
achieve a central venous and wedge pressure as close to normal as possible.
which was feasible in 13 (81.3%) patients. The remaining 3 patients were
optimized medically (5).
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Last year (2015), a single-arm, prospective, multicenter study, designed to
evaluate the performance and safety of the HMIII, enrolled 50 patients. The
primary endpoint was 6-month survival compared with the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS) data. The 6 month
survival was 92%, with 88% of patients continuing on support and 4%
transplanted, which exceeded the 88% goal. Major adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding
(8%), and debilitating stroke (8%). There were no pump exchanges, pump
malfunctions, pump thrombosis, or hemolysis events. Overall stroke rate was 12%
which was higher than expected (6).
In 2016, the first results from the Multicenter Study of MagLev Technology in
Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3
(MOMENTUM 3), a nonblinded randomized trial that comparing HMIII and HMII,
were published. The primary end point was a composite of survival free of
disabling stroke or pump replacement at 6 months.
Patients were randomly assigned to HMII or HMIII irrespective of treatment
strategy (bridge to transplant or destination therapy). The survival without stroke
or pump replacement was better in HMIII (86.2%) than in HMII recipients (76.8%),
with P<0.001 for noninferiority and P=0.04 for superiority. There were no
significant differences between the groups in the rates of death or disabling stroke.
Reoperation for pump malfunction was less frequent in HMIII than in HMII
recipients. Remarkably, there were no cases of pump thrombosis in the HMIII
arm, whereas 10.1% of HMII patients had this complication. There was no
difference in bleeding. Overall, HMIII was associated with better outcomes at 6
months, mostly due to fewer reoperations for pump malfunction (7).

Outcomes
Because all potential candidates for VAD are in New York Heart Association
(NYHA) III/IV class, there is a need to risk stratify patients in the advanced HF
cohort. Traditionally, an assessment of patients’ acuity is done and recorded as
INTERMACS profile. Several years ago Cowger et al.(8) introduced a HMII risk
score (HMRS), calculated as
HMRS = (0.0274 × [age in years]) − (0.723 × [albumin g/dl]) + (0.74 × [creatinine
mg/dl]) + (1.136 × [INR]) + (0.807 × [center LVAD volume <15*]). (Enter value of 1
if total center LVAD volume is <15 and 0 if ≥15).
The risk, predicted by the score, is categorized into low (<1.58), mid (1.58 to 2.48),
and high (>2.48), providing a good discrimination in terms of outcomes: a ninetyday mortality in these 3 groups was 4%, 16%, and 29%, respectively (p <
0.001)(8).
This year, two different groups of investigators applied this score to the
INTERMACS data and arrived to different conclusions.
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Kangar et al. found the score to be a weak tool for prognostication. At 90-days,
18% patients with high HMRS died, compared to 13% with medium risk and 7%
low risk patients. The 90-day and 1-year mortality prediction had an area under
curve at only 61% and 59%, respectively, making the score a poor discriminator of
the mortality risk (9).
In another study, the score was not simply applied to the INTERMACS data, but its
ability to predict outcomes was compared with INTERMACS profiles. Patients in
the highest and lowest HMRS group had a 90-day mortality of 12.9% and 4.6 % ,
respectively. However, the score provided better discrimination in terms of
mortality prediction than INTERMACS profiles. Moreover, after stratifying patients
within each INTERMACS profile by HMRS class, authors found that INTERMACS
profile 1 patients with a low-HMRS had a 90-day mortality similar to INTERMACS
profile 3 with a high HMRS. In other words, HMRS identified patients from lower
(poorer) INTERMACS profile with more favorable prognosis than in patients with
higher INTERMACS profile. Applied to patients with INTERMACS profile 1 and 2,
typically seen as unfavorable candidates for VAD implant, the score can identify
patients who should be offered the treatment because their risk in reality is not that
high. The score performed equally well in HMII and Heartware (10).
The outcomes of patients supported with Heartware devices for longer than 2
years were reported based on the data from the Registry to Evaluate the
HeartWare Left Ventricular Assist System (ReVOLVE), which is an investigatorinitiated multicenter, prospective, single-arm database established to collect postConformite Europeenne Mark clinical information on HeartWare. Overall survival
through 5 years was 59% (11).
Speaking about quality of life as a valid outcome, several authors suggested
integrating sexual function in the quality of life evaluation tools for patients with
LVADs (12)

Recovery
A large review article in two parts on ventricular recovery on VAD by Dandel and
Hetzer (13,14) was published in the very end of 2015 and was not included in the
last year summary. The authors underscore the higher recovery rates in
postcardiotomy syndrome and acute myocarditis, lower in nonischemic
cardiomyopathy, and rare in ischemic cases. Overall, the recovery due to LV
unloading occurs in less than 10% of patients. They also discuss in detail the
whole process of evaluation for recovery and weaning off LVAD.
Last year, the query of the United Network for Organ Sharing (UNOS) registry
found that LVAD explant due to recovery was done in 5% of patients, mostly
young and non-ischemic. In the first year, one third of these patients either died or
had heart transplant, therefore bringing the rate of true recovery down to slightly
over 3% (15).
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This year, analysis of the INTERMACS revealed similar low recovery rates: 0.9%
at 1-year, 1.9% at 2-year, and 3.1% at 3-year follow-up. Independent predictors of
device explantation for recovery were age <50 years (odds ratio [OR] 2.5),
nonischemic etiology (OR 5.4), time since initial diagnosis <2 years (OR 3.4),
suboptimal HF therapy before implant (OR 2.2), LV end-diastolic diameter <6.5 cm
(OR 1.7), pulmonary systolic artery pressure <50 mm Hg (OR 2.0), blood urea
nitrogen <30 mg/dL (OR 3.3), and axial-flow device (OR 7.6). Patients with
myocarditis (7.7%), postpartum cardiomyopathy (4.4%), and adriamycin-induced
cardiomyopathy (4.1%) had highest rates of device explantation for recovery. Use
of neurohormonal blockers on LVAD support was significantly higher in patients
who were explanted for recovery (16).
Partial recovery, i.e. LV improvement not reaching normal parameters, is far more
common. In patients supported with LVAD for at least 6 months, 5% of subjects
with ischemic cardiomyopathy and 21% of subjects with nonischemic
cardiomyopathy achieved left ventricular ejection fraction ≥40% (p = 0.034). The
degree of improvement by echocardiographic criteria was similar in recovered
hearts regardless of the etiology (17).
No difference was found in LV ejection fraction or volumes between axial flow and
centrifugal flow LVADs. LV ejection fraction increased significantly from a mean of
18% pre-VAD to 28% and 26% post-LVAD, respectively (18). By other data,
conversely, axial design provided a greater reduction of right atrial pressure,
pulmonary capillary wedge pressure, mean pulmonary artery pressure, and left
ventricular internal diameter during diastole, as well as greater improvement in
cardiac output (19).
In the process opposite to recovery, lack of LV function due to complete surgical
closure of the aortic valve may result in cardiac atrophy. One study noted that after
4 years on LVAD support, a heart weight only 280 g in a 220 pound man (20).

Candidate selection
Elderly
There is currently no established age limit for LVAD implant. When Mechanical
Circulatory Support Research Network was queried, patients ≥70 years of age
constituted only 14% of LVAD implants. Their rates of device thrombosis and
stroke were similar to younger patients, but older patients had more
gastrointestinal (GI) bleeds. Their unadjusted survival at 1 year was 75%
compared with 84% in younger patients, and at 2 years it was 65% versus 73% (P
=0.18). The only predictor of mortality was creatinine (HR 2.1, 95% CI 1.2-3.4; P =
.007). Creatinine >/=1.4 mg/dL was associated with a 1-year survival of 65%,
compared with 84% when the creatinine was <1.4 mg/dL (P = .009). If renal
function was normal, survival was similar to younger patients (21).
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Small Body Size
Outcomes in patients with body surface area < 1.5 m2 (mostly women) with HMII
were analyzed in the INTERMACS and found to be similar to the overall LVAD
population (22,23).
Adult Congenital Disease
In 2016, the American Heart Association published a scientific statement on
transplantation and mechanical circulatory support in congenital heart disease.
The document approaches MCS in congenital cardiac cases quite cautiously,
saying that despite an overall growth in VADs, the volume of implants for
congenital heart disease has not grown. Complexity of anatomy and physiology,
together with multiple prior surgeries and interventions, creates many challenges,
especially because in most cases the ultimate goal is cardiac transplant.
Moreover, authors state that MCS is associated with significant morbidity and
uncertain long-term outcomes in adult patients with congenital heart disease. Most
currently available information is coming from case reports and small series. There
is a need for a multi-institutional MCS single-ventricle registry in order to better
define selection criteria for MCS (24).
Meanwhile, case reports and small series keep being published. In a series of 5
patients with a failing single-ventricle circulation (hypoplastic left heart syndrome,
pulmonic atresia with intact ventricular septum, tricuspid atresia, double-outlet right
ventricle with unbalanced atrioventricular canal, and situs inversus with pulmonary
atresia and left atrioventricular valve atresia, four of them with Fontan and one with
bidirectional Glenn), MCS helped to bridge three of them to heart transplantation
(25). Another Fontan patient with acute ventricular failure was sequentially bridged
to transplant with temporary and then durable support devices (26). A detailed
discussion of the approach to decision, candidate selection, and surgical technique
of MCS in Fontan patients is given by Woods et al.(27).
In another case, MSC was used to successfully bridge an adult with congenitally
corrected transposition of the great arteries and situs inversus (28).

Management of patients on LVAD support
There is a growing realization that LVAD usually provides incomplete
compensation of HF, and therefore hemodynamic monitoring and medical
management may be of value.
Specifically, left atrial pressure monitoring with a wireless microelectromechanical
system pressure sensor (Titan, ISS Inc., Ypsilanti, MI, USA), placed during LVAD
implantation in 4 patients, demonstrated good correlation between sensor
pressure and pump speed, LV and left atrial size and pulmonary capillary wedge
pressure, respectively (r= 0.92-0.99, p < 0.05) (29).
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Remote hemodynamic with Cardiomems (St. Jude Medical, Inc., St. Paul, MN)
was also tested in VADs with promising results (30,31).
Because of incomplete hemodynamic compensation with LVAD, use of HF
medications after LVAD can be of value. In the INTERMACS, angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were
used in 38%, beta blockers in 55%, mineralocorticoid receptor antagonists in 40%,
and loop diuretics in 87% of patients before implant. By 3 months after implant,
the rates were 50% for ACE inhibitors or ARBs, 68% for beta-blockers, 33% for
mineralocorticoid receptor antagonists and 68% for loop diuretics (32).
Importance of medical management of HF even on LVAD support was proven by
Grupper et al. In a retrospective review they found that a statistically significant
improvement in NYHA class, six minute walk distance, ejection fraction, decrease
in LV end-diastolic diameter index and LV mass index, and a sustained reduction
in N-terminal pro B-type natriuretic peptide occurred to a greater extent in those
who were treated with ACE inhibitors and beta blockers after LVAD than in
patients who did not receive these therapies. Also, a combined end point of
cardiovascular death or HF hospitalization at 6 months was significantly reduced in
patients receiving medical management (p = 0.013) associated primarily with a
12.1% absolute reduction in HF-related hospitalizations (33).
It appears that pacing can have consequences in LVAD patients as well. In a
patient with Heartware and intermittent RV pacing, episodes of pacing were
associated with hemodynamic compromise including a decrease in the systemic
blood pressure, pulse pressure, pulsatility index, and estimated flow, recorded by
the VAD control module, and an increase in the central venous pressure and
severity of tricuspid regurgitation. All the changes reversed with intrinsic rhythm
and conduction (34).
Obesity
Some patients with end stage cardiomyopathy and obesity receive LVAD as a
bridge to transplant, but then are unable to lose weight, and never become
transplant candidates. Several cases of bariatric surgery were reported last year,
and there was another one in 2016 – a patient underwent laparoscopic sleeve
gastrectomy, achieved significant weight loss, and cardiac transplantation was
performed (35)
Arrhythmias
Interesting data were obtained on interrogation of ICDs of LVAD patients.
Ventricular arrhythmia was occurring more often after the implantation, including
treated-zone ventricular arrhythmias ( p < 0.01), monitored-zone arrhythmias (p <
0.01), antitachycardia pacing - terminated episodes (p < 0.01), and shocks (p =
0.01), although administered shocks later decreased (p < 0.01). Presence of a
preimplant ventricular arrhythmia was associated with postoperative episodes (OR
4.31; CI 1.5-12.3, p < 0.01). ICD shocks either before or after implant were not
associated with survival (36).
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Same phenomenon was described by Yap et al., but their follow-up was longer.
Overall, 30% of patients experienced ventricular arrhythmia on VADs. The burden
of ventricular arrhythmia followed a U-shaped curve, with the highest incidence in
the first postoperative month, a nadir at 15 to 18 months, and a rise after that time.
Pre-LVAD ventricular arrhythmia was the only independent predictor of post-VAD
arrhythmia. Post-LVAD arrhythmia was not associated with increased mortality
(37).
Similar proportion (28%) of the VAD patients experienced ventricular arrhythmia in
another study (70% of them had ventricular tachycardia and 30% had ventricular
fibrillation), with history of ventricular arrhythmia or atrial fibrillation before VAD
being the most powerful predictors of ventricular arrhythmia post-VAD. However,
unlike in the last paper, ventricular arrhythmia after LVAD was associated with a
significantly higher risk of all-cause mortality (HR 7.28; 95% CI 3.50-15.15; P <
.001) (38).
Not surprisingly, discussions about role of implantable cardioverter-defibrillators
(ICDs) in VAD patients continued in 2016. A meta-analysis of three observational
studies (39-41) with a total of 292 patients (69.5% with ICD versus 30.5% without
ICD) found no survival benefit in patients with ICD (42). It would be difficult to
expect a different result since none of the three studies included in the analysis
showed such benefit (MG).
Another systematic review and meta-analysis on ventricular arrhythmia in LVAD
population included six observational studies with a total of 937 subjects, but
because older studies were included, only 40% of them were on continuous-flow
pumps. During a mean follow-up of 7 months, 16% died in the ICD group vs 32%
in the no-ICD group. Presence of an ICD was associated with a 39% relative risk
reduction in all-cause mortality (RR: 0.61; 95% CI: 0.46 to 0.82; p < 0.01).
Unfortunately, in a subset of patients supported with continuous flow VAD, survival
difference did not reach significance (43).
The search of UNOS database revealed that presence of ICDs in patients bridged
to transplantation with LVADs was not associated with lower total or
cardiovascular mortality on the waiting list; however, there were numerically fewer
arrhythmic deaths in the ICD group (44).
Because of conflicting results and scanty data, there were calls for MADIT-VAD
trial (45,46).
Anecdotally, subcutaneous ICD inappropriately shocked a patient with LVAD
because R waves were diminished and superimposed by electric noise caused by
the LVAD. Oversensing of electromagnetic interference led to multiple shocks.
Replacing subcutaneous defibrillator with a usual transvenous system eliminated
the problem. Obviously, relying on surface ECG with smaller R waves may create
additional difficulties for arrhythmia-recognizing algorithm in subcutaneous ICD
(47).
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LVAD and kidneys
Longitudinal changes in renal function after LVAD were reported previously. Last
year, we cited the paper of Brisco et al. (48) who showed that although renal
function, after initial improvement, deteriorates on LVAD support, in patients with
lower baseline glomerular filtration rate the function is still better than before the
implant. This was confirmed in 2016 by Raichlin et al. who demonstrated that
when renal function before the LVAD was stratified by glomerular filtration rate into
≤40 and >40 ml/min/1.73 m, dynamic changes after LVAD were different. In all
patients, renal function initially improved and then declined. But in a year after the
implant, patients with more preserved renal function at baseline returned to the
pre-VAD values, while those with more severe impairment pre-VAD had better
function one year after. Although patients with worse baseline impairment required
hemodialysis after VAD more often, this group of patients can benefit the most
from improved hemodynamics on LVAD support (49).
Hemodialysis in LVAD population remains a topic of interest. In the past, very few
articles addressed the issue (50-53). There was some further progress in 2016.
Two groups of authors described normal maturation of arteriovenous fistula with
subsequent uncomplicated hemodialysis in a total of four patients. Calenda et al.
reported a series of 3 patients on continuous LVAD support who had dialysis via
fistula which also matured normally (54,55).
Intermittent inpatient hemodialysis (170 sessions in 9 patients with HMII) was well
tolerated, with only 6.5% of sessions terminated early, mainly because of
hypotension. Six out of nine patients (66.7%) recovered kidney function and
became dialysis independent (56).

LVAD and mitral valve
There is no consensus on surgical correction of mitral regurgitation (MR) during
LVAD implantation. Sometimes, severity of MR decreases after LVAD. Tanaka et
al. studied 110 patients in whom MR resolved after LVAD implantation, with
surgical correction or spontaneously. Surgical correction was associated with
better hemodynamics during follow-up: lower pulmonary wedge pressure (12 mm
Hg vs 17 mm Hg, p = 0.015) and pulmonary vascular resistance (1.7 vs 2.0 Wood
units, p = 0.047). Overall survival rate and freedom from recurrent MR were also
significantly better in the surgical correction group compared with the spontaneous
correction group (1-year survival, 69.6% +/- 6.4%, vs 59.4% +/- 6.9% p = 0.030;
1-year freedom from recurrent MR, 95.0% +/- 3.5% vs 76.2% +/- 7.5%, p = 0.028.
Aggressive surgical mitral valve intervention during LVAD implantation may be
recommended (57).
Concurrently, a retrospective review of patients with significant (greater than mild)
residual MR after LVAD implantation demonstrated a larger RV size, worse RV
function, higher pulmonary arterial pressures, and shorter time to rehospitalization
and death (58).
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Anticoagulation in VADs
There is an ongoing discussion on whether aspirin should be a mandatory
component of management of patients on LVAD support. Studied in the
experiment, aspirin reduced platelet activation under low shear stress, but was
minimally effective at the shear stress produced with VAD (59).
Last year, we included the results of the TRACE U.S. (STudy of Reduced AntiCoagulation/Anti-platelEt Therapy in Patients with the HeartMate II LVAS), which
looked into safety of reduced anti-thrombotic therapy in HMII recipients, who had
bleeding events. The enrolled 100 participants were outpatients on warfarin only
(38%), aspirin only (28%), or no anti-thrombotic agent (34%). Freedom from
ischemic stroke at 1 year was 93.8% ± 2.5%, and freedom from device thrombosis
was 92.7% ± 2.7%. Despite reduced anticoagulation and antithrombotics, a
subsequent bleeding event occurred in 52%, although there were no intracerebral
bleeds. There was no comparison of strategies against each other (60).
In 2016, the results of European TRACE study were published. Unlike in the US
study, majority of participants (94%) did not have prior bleeding episodes. Rather,
they were managed without antithrombotic agents - on anticoagulation only, with
median INR 2.3 – based on physicians’ preferences. At 2 years, freedom from
bleeding, ischemic stroke, hemorrhagic stroke, and pump thrombosis was 81% +/6%, 96% +/- 2%, 94% +/- 3%, and 94% +/- 3%, respectively. Investigators
concluded that warfarin alone without aspirin may help to reduce the incidence of
major bleeding without increasing the risk of thromboembolic events, including
ischemic stroke and pump thrombosis (61).
Unlike with the aspirin, nobody questions the need for anticoagulation. In view of
recent rise in pump thrombosis (62), there are ongoing efforts to find the optimal
protocol for anticoagulation management in LVAD patients. An important step was
accomplished in 2016 with the completion and publication of the PREVENT
(PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management)
trial. This was a prospective, multi-center, single-arm, non-randomized study of
300 patients with HMII. Investigators agreed on the best practices in terms of
implant technique, anti-coagulation strategy, and pump speed management. The
study looked at the ability of these practices to prevent early (<3 months) pump
thrombosis.
The study investigators hypothesized that they will achieve a ≤ 4% rate of pump
thrombosis at 3 months with the implementation of recommended rules. In fact, the
pump thrombosis rate was 2.9% at 3 months and 4.8% at 6 months. Adherence to
key recommendations included 78% to surgical recommendations, 95% to heparin
bridging, and 79% to pump speeds >/=9,000 rpms. Full adherence to all three
components resulted in a significantly lower risk of pump thrombosis (1.9% vs
8.9%; p < 0.01) and lower composite risk of suspected thrombosis, hemolysis, and
ischemic stroke (5.7% vs 17.7%; p < 0.01) at 6 months (63). The summary of
recommendations from the trial is summarized below:
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Surgical recommendations






Adequately sized pocket
Inflow cannula parallel to the septum
Outflow graft to the right of mid-sternum in order not to compress
RV
Pump below the diaphragm
Fixate the pump to the diagram or chest wall

Anticoagulation/antiplatelet management





Bridging with low molecular weight heparin within 48 hours of
implant, PTT goal 40-45 sec, increase goal to 50-60 sec by 96
hours
Start warfarin within 48 hours of implant, INR goal 2-2.5, stop
heparin when achieved
Aspirin 81-325 mg/day 2-5 days after implant if no bleeding
INR goal stays 2-2.5 indefinitely

Pump speed>9000 rpms
Mean arterial pressure <90 mmHg

As more centers are switching from traditional monitoring of heparin concentration
by PTT to antiXA factor, there are some discrepancies observed. PTT is a test that
reflects an overall status of anticoagulation, while antiXa specifically measures
heparin concentration. Last year Adatya et al. (64) found disturbingly high
discordance in paired blood samples. The results of the two essays were
considered concordant if they both indicated that anticoagulation was within
therapeutic, subtherapeutic, or supratherapeutic range. The discordance was
63.8% in the bridging cohort (initial anticoagulation after the implant) and 84.2% in
the pump thrombosis cohort, where therapeutic level of anticoagulation is critically
important. The most common pattern of discordance was a supratherapeutic PTT
value and a therapeutic anti-Xa level (49.1% for bridging vs. 75.8% for pump
thrombosis; p < 0.001), likely because hemolysis per se, as well as elevated INR,
which was frequent in these patients, can prolong PTT. Authors concluded that
Anti-Xa assay may therefore give a more accurate guidance on heparin
concentration in this population (64).
This year, it was confirmed that the type of discrepancy where PTT is prolonged
and antiXA is therapeutic is very common in LVAD population and is observed in
68-84% of patients when PTT is above 100 sec or 112 sec, respectively. Rate of
bleeding within 30 days was similar with antiXa vs PTT monitoring, while the rate
of pump thrombosis seemed to favor PTT monitoring. At the current state of
knowledge, it seems reasonable to use both tests in parallel (65,66). Specifically,
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authors suggest that in an uncomplicated post-operative patient, escalating
heparin when PTT is prolonged and antiXA ia therapeutic may unnecessarily
increase bleeding risk. Conversely, in cases of device thrombosis, heparin titration
based on both PTT and anti-Xa may provide more adequate anticoagulation and
possibly improve outcomes (Ton et al).

Noncardiac surgery
Outcomes of noncardiac surgery in LVAD population were reported before, but the
analysis of large cohort from the National Inpatient Sample Database, published in
2016, is of interest. Noncardiac surgery is common and is done in over 20% of
patients on LVAD support. After surgery, these patients experienced more wound
infections than all patients with VADs (9.1 vs. 4.6%, p = 0.004), greater bleeding
complications (44.0 vs. 24.8%, p < 0.001) and were more likely to develop any
complication (87.2 vs. 82.0%, p = 0.001). Mortality difference did not reach
significance. Authors suggest that even low-risk non-cardiac surgery should be
performed in VAD centers (67).

Complications of the VADs
Stroke
In a large single-center study, strokes occurred in 13.2% of patients on VADs.
Treatment of ischemic stroke included intra-arterial embolectomy when
appropriate; while treatment of intracerebral hemorrhage included reversal of
coagulopathy. Most strokes (80%) were ischemic. Half of patients with
hemorrhagic stroke and third of those with ischemic stroke died, but some
survivors of ischemic event underwent successful heart transplant (68).
The anticoagulation reversal may vary in between institutions as well as individual
cases. The report by Wong et al. shows that administration of 4-factor
prothrombin complex concentrate may safely shorten the time to reversal and
decrease the requirements in fresh frozen plasma (69).
In the series of 5 patients with LVAD, two of them therapeutic on warfarin, with
acute ischemic stroke, who underwent thrombectomy with or without
thrombolytics, none developed intracerebral hemorrhage as a complication. Their
functional status improved (70). Being on a VAD and therapeutically
anticoagulated should not be considered a contraindication to thrombectomy.

Pump thrombosis: diagnosis
Most of the literature on pump thrombosis was focused on the events in patients
with HMII. In 2016, a detailed analysis of diagnosis and treatment of Heartware
thrombosis was described by Scandroglio et al. (71).
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Pump thrombosis was diagnosed by laboratory signs of hemolysis, LVAD alarms
and waveforms, imaging, and acoustic analysis of the pump noise. They classified
all obstructions to blood flow into 1) pre-pump, with thrombus obstructing the inflow
cannula (0.037 events per patient-year); 2) intra-pump (0.1 events per patientyear); and 3) post-pump, with the thrombus in the outflow graft or stenosis of the
anastomosis to the aorta (0.006 events per patient-year). While intra-pump
thrombosis was accompanied by power spikes, pre-and post pump obstructions
caused low flow alarms, but the onset was more abrupt in the inflow cannula
obstruction (Figures 4, 5).
Pre-pump obstruction was treated by washout maneuver (success rate, 100%),
thrombolysis (success rate, 56%), or pump exchange (success rate, 100%). In
washout maneuver, the LVAD was turned off and then back on, in order to
dislodge the clot. There were cases of peripheral embolization, but carotid arteries
were protected by filters, introduced bilaterally to capture thrombus released from
the pump, and to prevent stroke.
For intra-pump obstruction, thrombolysis was successful only in 33% cases, and
pump exchange in 94%; most patients who died were in this group. For post-pump
obstruction, two patients were successfully treated with stenting, and other two
were left untreated (71).

Figure 4. Abrupt drop of flow due to obstruction of the inflow cannula (Reproduced
from Scandroglio et al.(71), with permission.
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Figure 5. Gradual decrease of flow due to obstruction in the outflow graft.
Reproduced from Scandroglio et al. (71), with permission.
We reported the case of complete pump thrombosis with normal LDH (72).

Pump thrombosis: treatment
Comparing surgical (device exchange) and conservative approaches to pump
thrombosis, the superiority of surgical management was again confirmed. The 1year freedom from stroke or death was 87.5% and 49.5% in the surgical and
medical cohorts, respectively (P=0.027). Resolution of a primary hemolysis event
without CVA or death occurred in 87.5% patients treated with surgical
interventions and in 52.0% on medical therapy alone. A similar association
between treatment and outcome was noted in the 15 recurrent hemolysis events
(73).
A meta-analysis on medical management of pump thrombosis was published by
Dang et al. (74).
With different medical interventions, the success rates were as follows:


Heparin alone 23%



Heparin +IIB/IIIA antagonists or direct thrombin inhibitor 49%



IIB/IIIA or direct thrombin inhibitor 49%



Thrombolytics alone or in combination with other agents 66%
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The highest rate of major bleeding was observed in the combination of heparin
and IIB/IIIA antagonists or direct thrombin inhibitor at 35%. This therapy also
caused the maximal amount of intracerebral bleeds (18%). Death was most
commonly reported after thrombolytics (20%), and the rate of intracerebral
hemorrhage was 17%, but only when thrombolytics were used in combination with
two or three other agents such as IIB/IIIA antagonists and direct thrombin
inhibitors.
In yet another comparison of device exchange or systemic thrombolysis for pump
thrombosis, patients were not randomized. If treatment was started in the first 24
hours after the diagnosis of pump thrombosis, thrombolytics were given,
specifically either Tenecteplase (100 U/10 kg body weight) or Alteplase (1 mg/kg
body weight) given as bolus infusions over 1 hour. Heparin was stopped for the
infusion, but restarted when it was over. If there was more than 24 hours since the
beginning of pump thrombosis, pump exchange was performed. A 90-day survival
was 91.0% in surgical management and 89.3% in systemic thrombolysis.
Thrombolytics were associated with fewer blood transfusions, shorter intensive
care unit stay, However, 90-day even free survival was 89% in the device
exchange group and 60.7% in the thrombolytics group (P=0.027), and 2 year
event free survival was 55.2% and 18%, respectively (p = 0.006), favoring pump
exchange (75).

Gastrointestinal Bleeding
Degradation of von Willebrand factor in LVAD was tested in the mock loop at
speed range 8600 to 11400 rpm, with no difference found, meaning that speed
reduction by itself does not result in better preservation of this factor (76).
Sheer stress, ADAMTS-13, and dysfunctional platelets with abnormal aggregation
are all essential in the development of LVAD related coagulopathy (77). In patients
with HMIII, the preservation of von Willebrand factor was much better than with
HMII (78).
Although platelet dysfunction and acquired von Willebrand syndrome make it
easier to bleed, the source of GI bleeding in LVAD is almost always arteriovenous
malformations in the small bowel, and their origin is poorly understood. Patel et al.
hypothesized that easily accessible nasal mucosa can be representative of GI
tract. In 80 patients with VAD, they performed a bedside nasal endoscopy and
looked for hypervascularity (Figure 6). This was present in 63%, 57%, and 20% of
the LVAD, HF, and control groups, respectively (p = 0.018). Although the
prevalence was similar, the severity of nasal hypervascularity was significantly
higher in the LVAD group compared with the HF group. Hypervascularity was
strongly associated with GI bleeding in the LVAD cohort: the incidence was 32% in
subjects with hypervascularity compared with 0% in subjects with normal mucosa
(p = 0.023) (79). Similar prevalence of arteriovenous malformations in HF and
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LVAD is an interesting finding which likely means that changes related to VADs
are not responsible for growth of small bowel arteriovenous malformations.

Figure 6. Arteriovenous malformation in the small gut and in nasal mucosa.
Reproduced from Patel et al. (79), with permission.
Anecdotally, a patient who had multiple episodes of GIB after LVAD due to
angiodysplastic lesions in the upper GI tract, managed with heparin alone, warfarin
alone with subtherapeutic or therapeutic INR, topical argon plasma coagulation of
the lesions, and being off aspirin, stopped bleeding only when anticoagulation was
changed to apixaban 2.5 mg twice daily, and there was not a single episode in the
next year (80).
In a single center retrospective study, concomitant use of antidepressants in LVAD
patients, specifically selective serotonin reuptake inhibitors, was associated with
higher rate of GI bleeding. Both unadjusted relative risk (2.35 with 95% CI, 1.05–
5.28; p = 0.04), and odds ratio after adjusting for age, sex, and use of GI
prophylactic agents (3.72 with 95% CI,1.16–11.89; p = 0.03) indicated connection
between the two variables (81).

Infections in LVADs
The review on endocarditis in VAD patients was published in 2016. LVADassociated endocarditis is defined as clinical evidence of pump and/or cannula
infection along with the presence of vegetation on echocardiography or a vascular
phenomenon as defined by modified Duke's criteria. Mortality is high around 60%.
The common pathogens include Staphylococcus, Pseudomonas and
Streptococcus species, as well as fungi. Aggressive management of infection, with
prompt device removal and prolonged antibiotic therapy targeting the specific
organism, is crucial to prevent catastrophic events, and the threshold for use of
antifungal agents such as fluconazol should be low (82).
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Right ventricular failure
Right ventricular failure after LVAD remains a serious problem, and no single
measurement or criterion can reliably predict it. A review paper on predictors of RV
failure after LVAD implant was published by Neyer et al. Clinical right HF, with the
need for inotropic support and occurring more than 30 days after discharge from
the LVAD implant (late right heart failure) was studied by Rich et al. This
complication developed in 8% of patients after a median time of 480 days on
support. These patients had worse quality of life, poorer functional capacity by 6minute walk distance, and more rehospitalizations. A higher preoperative blood
urea nitrogen and increased central venous pressure-to-pulmonary capillary
wedge pressure ratio were independent predictors of this condition (83).
In terms of treatment of RV failure, both planned implantation of biventricular pump
(84) and use of two Heartware devices are viable options. In a series of 13
patients (10 of them INTERMACS level 1, including seven patients on
extracorporeal life support or intra-aortic balloon pump), transplantation was
successfully performed in 5 patients, and overall survival for the entire cohort was
54%. RVAD pump thrombosis occurred in 4 cases (85).
The need of RVAD + LVAD before transplantation is independently associated
with post-transplant mortality (hazard ratio 1.22, 95% confidence interval 1.011.49, p = 0.04) (86).

Driveline fracture
Driveline fracture is a serious complication. To our knowledge, the largest study on
driveline fracture and a procedure for full external lead replacement was published
in our journal.
A total of 321 repairs were attempted in 297 patients with suspected isolated
external lead damage after a median of 2 years of support. In 37 (12.5%) patients,
attempts at external repair were unsuccessful due to concomitant internal lead
damage. 31 patients (10.4%) had additional serious malfunctions after lead repair
resulting in 17 with repeat repairs and 14 who continued on ungrounded cables,
and ultimately 14 of these 31 patients required pump exchanges. 27 of the 297
patients (9.1%) with lead repairs had only minor additional problems, including
cuts or abrasion in the insulation which was fixed with tape or external
reinforcement. There was only one catastrophic failure during attempted lead
repair requiring emergent pump exchange. Three patients died within 14 days of
attempted repair related to continued percutaneous lead damage. Majority (68%)
have had no recurrence of lead problems. Authors provided an algorithm for
evaluating potential lead damage (87).
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